Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
24.46
USD
|
-0.12%
|
|
+2.73%
|
-17.14%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
553.3
|
510.7
|
486.2
|
718.5
|
1,376
|
1,153
|
-
|
-
|
Enterprise Value (EV)
1 |
553.3
|
510.7
|
329.7
|
566.8
|
1,396
|
872.2
|
792.8
|
646.1
|
P/E ratio
|
-5.35
x
|
-4.27
x
|
-5.76
x
|
-4.85
x
|
-7.49
x
|
-21.6
x
|
66.6
x
|
12.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
25.4
x
|
9.32
x
|
7.38
x
|
3.64
x
|
2.76
x
|
2.19
x
|
EV / Revenue
|
-
|
-
|
17.2
x
|
7.36
x
|
7.49
x
|
2.76
x
|
1.9
x
|
1.23
x
|
EV / EBITDA
|
-
|
-
|
-1.91
x
|
-4.43
x
|
-
|
-19.1
x
|
173
x
|
10.4
x
|
EV / FCF
|
-14
x
|
-5.75
x
|
-2.48
x
|
-4.71
x
|
-19.6
x
|
-36.8
x
|
40.3
x
|
9.41
x
|
FCF Yield
|
-7.16%
|
-17.4%
|
-40.3%
|
-21.2%
|
-5.09%
|
-2.72%
|
2.48%
|
10.6%
|
Price to Book
|
-
|
-
|
4.06
x
|
4.67
x
|
-
|
4.55
x
|
4.24
x
|
-
|
Nbr of stocks (in thousands)
|
22,567
|
29,250
|
30,482
|
36,848
|
46,614
|
47,118
|
-
|
-
|
Reference price
2 |
24.52
|
17.46
|
15.95
|
19.50
|
29.52
|
24.46
|
24.46
|
24.46
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/9/22
|
3/8/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
19.14
|
77.06
|
186.4
|
316.4
|
418.3
|
526.5
|
EBITDA
1 |
-
|
-
|
-172.8
|
-128
|
-
|
-45.78
|
4.574
|
61.99
|
EBIT
1 |
-54.74
|
-104.3
|
-173.4
|
-131.2
|
-106.6
|
-69.25
|
5.833
|
101.6
|
Operating Margin
|
-
|
-
|
-906.12%
|
-170.28%
|
-57.22%
|
-21.89%
|
1.39%
|
19.3%
|
Earnings before Tax (EBT)
1 |
-52.53
|
-103.3
|
-83.95
|
-142.1
|
-159.9
|
-77.11
|
2.361
|
109.5
|
Net income
1 |
-52.55
|
-103.3
|
-83.99
|
-135.7
|
-160.9
|
-58.88
|
18.89
|
81.2
|
Net margin
|
-
|
-
|
-438.85%
|
-176.05%
|
-86.33%
|
-18.61%
|
4.51%
|
15.42%
|
EPS
2 |
-4.580
|
-4.090
|
-2.770
|
-4.020
|
-3.940
|
-1.134
|
0.3672
|
1.934
|
Free Cash Flow
1 |
-39.64
|
-88.85
|
-132.8
|
-120.4
|
-71.05
|
-23.72
|
19.65
|
68.64
|
FCF margin
|
-
|
-
|
-693.81%
|
-156.26%
|
-38.12%
|
-7.5%
|
4.7%
|
13.04%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
429.67%
|
110.73%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
104.05%
|
84.53%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/9/22
|
3/8/23
|
2/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
5
|
3.138
|
12.89
|
17.48
|
18.78
|
27.91
|
31.6
|
37.5
|
47.72
|
69.55
|
70.17
|
75.4
|
82.45
|
89.23
|
94.25
|
EBITDA
1 |
-42.74
|
-45.23
|
-32.39
|
-30.84
|
-31.44
|
-
|
-25.81
|
-
|
-
|
-
|
-20.44
|
-18.53
|
-11.93
|
-6.125
|
-
|
EBIT
1 |
-42.82
|
-45.58
|
-32.74
|
-31.44
|
-32.88
|
-34.16
|
-27.15
|
-24.27
|
-25.15
|
-30.08
|
-25.48
|
-23.4
|
-17.28
|
-12.78
|
-3.07
|
Operating Margin
|
-856.48%
|
-1,452.36%
|
-253.92%
|
-179.83%
|
-175.09%
|
-122.41%
|
-85.92%
|
-64.73%
|
-52.69%
|
-43.24%
|
-36.31%
|
-31.03%
|
-20.96%
|
-14.33%
|
-3.26%
|
Earnings before Tax (EBT)
1 |
-47.1
|
57.56
|
-36.6
|
-33.49
|
-35.69
|
-36.29
|
-29.93
|
-73.72
|
-23.34
|
-32.92
|
-26.34
|
-25.48
|
-17.39
|
-14.01
|
-
|
Net income
1 |
-47.11
|
57.55
|
-36.61
|
-26.92
|
-35.71
|
-36.43
|
-30.13
|
-74.04
|
-23.59
|
-33.15
|
-21.63
|
-20.14
|
-13.05
|
-9.699
|
-
|
Net margin
|
-942.16%
|
1,833.84%
|
-283.94%
|
-153.98%
|
-190.13%
|
-130.55%
|
-95.35%
|
-197.45%
|
-49.42%
|
-47.66%
|
-30.82%
|
-26.71%
|
-15.83%
|
-10.87%
|
-
|
EPS
2 |
-1.550
|
1.910
|
-1.170
|
-0.8400
|
-1.020
|
-0.9900
|
-0.8000
|
-1.940
|
-0.5700
|
-0.6300
|
-0.4012
|
-0.3579
|
-0.2719
|
-0.1757
|
-0.1200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/9/22
|
5/5/22
|
8/4/22
|
11/9/22
|
3/8/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
20.1
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
157
|
152
|
-
|
280
|
360
|
506
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-39.6
|
-88.9
|
-133
|
-120
|
-71.1
|
-23.7
|
19.7
|
68.6
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-57.5%
|
-103%
|
-82.4%
|
-26.1%
|
7.25%
|
19.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-31.4%
|
-41.9%
|
-32.2%
|
-7.2%
|
-1.58%
|
-
|
Assets
1 |
-
|
-
|
267.8
|
323.8
|
499.8
|
817.9
|
-1,195
|
-
|
Book Value Per Share
2 |
-
|
-
|
3.930
|
4.180
|
-
|
5.370
|
5.770
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.28
|
-
|
-
|
0.28
|
0.11
|
0.39
|
0.41
|
0.34
|
Capex / Sales
|
-
|
-
|
-
|
0.36%
|
0.06%
|
0.12%
|
0.1%
|
0.06%
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/9/22
|
3/8/23
|
2/28/24
|
-
|
-
|
-
|
Last Close Price
24.46
USD Average target price
48.91
USD Spread / Average Target +99.96% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.14% | 1.15B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|